Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment

Medicare Advantage plans have been associated with increased screening rates. But managed care tactics and narrow networks may be a disadvantage for people needing care.

MHE Associate Editor, Briana Contreras, spoke with CEO of Inteliquet, a cancer solutions provider that strives to match patients to clinical trials accurately and promptly in healthcare, Marie Lamont. In this episode Marie discusses the challenges that have affected clinical trials and cancer screenings and how to get trials back on track through technology to avoid the wave of undiagnosed patients post-COVID. She also shared how broadening them through diversity can improve trials.

This year's most-read cancer news included researchers finding a possible liver cancer immunotherapy, cancer patients facing many negative impacts from COVID-19 and more.

This episode of Tuning Into The C-Suite welcomes our first of many episodes part of the new “Meet the Board” podcast series. Listeners will now hear from a member of Managed Healthcare Executive's Editorial Advisory Board once a month at the end of each month. The first guest featured is Physician and former Executive VP of the American Cancer Society, Otis Brawley. Brawley is a Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.

Positive results for Adcetris (brentuximab vedotin) were reported in The New England Journal of Medicine. Further research will include a look at the cost effectiveness of Adcetris.

Dana-Farber Cancer Institute tool evaluates the probability of having genetic mutations that confer elevated risk for 18 cancers.